Jorge A. Marrero
The University of Texas Southwestern Medical Center
3 papers in the Anchorcite directory, published between 2003 and 2018, cited 13,242 times in total.
ORCID profileResearch topics
- Hepatocellular Carcinoma Treatment and Prognosis · 2 papers
- Head and Neck Cancer Studies · 2 papers
- Hepatitis B Virus Studies · 1 paper
- Hepatitis C virus research · 1 paper
- Liver Disease Diagnosis and Treatment · 1 paper
- Liver Disease and Transplantation · 1 paper
Frequent co-authors
- Laura Kulik · 2 papers
- Claude B. Sirlin · 2 papers
- Andrew Xiuxuan Zhu · 2 papers
- Richard S. Finn · 2 papers
- Michael M. Abecassis · 2 papers
- Lewis Rowland Roberts · 2 papers
- Julie K. Heimbach · 2 papers
- Chun Tao Wai · 1 paper
Papers
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology · 2018 · 4,629 citations
Purpose and ScopeThis guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC).A guidance document is different from a guideline.Guidelines are developed by a multidisciplinary panel of experts who rate the quality…
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology · 2003 · 4,492 citations
Information on the stage of liver fibrosis is essential in managing chronic hepatitis C (CHC) patients. However, most models for predicting liver fibrosis are complicated and separate formulas are needed to predict significant fibrosis and cirrhosis. The aim of our…
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology · 2017 · 4,121 citations
Potential conflict of interest: Laura M. Kulik is on the advisory board for Gilead, Bayer, Eisai, Salix, and Bristol‐Myers Squibb. Richard Finn consults for Pfizer, Bayer, Novartis, Merck, and Bristol‐Myers Squibb. Claude B. Sirlin consults for and has received grants…
Metadata from OpenAlex (CC0).